Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

936 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Why actively promote vaccination in patients with cirrhosis?
Loulergue P, Pol S, Mallet V, Sogni P, Launay O; GEVACCIM Group. Loulergue P, et al. Among authors: pol s. J Clin Virol. 2009 Nov;46(3):206-9. doi: 10.1016/j.jcv.2009.05.006. Epub 2009 Jun 4. J Clin Virol. 2009. PMID: 19501019 Review.
Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P; GER-CYT-RIBANON group. Poynard T, et al. Among authors: pol s. J Viral Hepat. 2003 May;10(3):197-204. doi: 10.1046/j.1365-2893.2003.00427.x. J Viral Hepat. 2003. PMID: 12753338 Clinical Trial.
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.
Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Payan C, et al. Among authors: pol s. J Viral Hepat. 2005 Jul;12(4):405-13. doi: 10.1111/j.1365-2893.2005.00605.x. J Viral Hepat. 2005. PMID: 15985012
Improving anti-hepatitis C virus therapy.
Pol S, Mallet VO. Pol S, et al. Expert Opin Biol Ther. 2006 Sep;6(9):923-33. doi: 10.1517/14712598.6.9.923. Expert Opin Biol Ther. 2006. PMID: 16918259 Review.
Improving anti-HCV therapy.
Pol S, Mallet VO. Pol S, et al. Discov Med. 2006 Oct;6(35):187-90. Discov Med. 2006. PMID: 17234140 Free article. Review.
Reversibility of cirrhosis in HIV/HBV coinfection.
Mallet VO, Dhalluin-Venier V, Verkarre V, Correas JM, Chaix ML, Viard JP, Pol S. Mallet VO, et al. Among authors: pol s. Antivir Ther. 2007;12(2):279-83. Antivir Ther. 2007. PMID: 17503671
936 results